dc.contributor.author | Konac, Ece | |
dc.contributor.author | Kiliccioğlu, Ilker | |
dc.contributor.author | Sogutdelen, Emrullah | |
dc.contributor.author | Dikmen, Asiye U. | |
dc.contributor.author | Albayrak, Gulsah | |
dc.contributor.author | Bilen, Cenk Y. | |
dc.date.accessioned | 2019-12-12T06:40:35Z | |
dc.date.available | 2019-12-12T06:40:35Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1535-3702 | |
dc.identifier.uri | https://doi.org/10.1177/1535370217728499 | |
dc.identifier.uri | http://hdl.handle.net/11655/16579 | |
dc.description.abstract | Development of metastatic castration-resistant prostate cancer is a result of the lack of an apoptotic response by the tumor cells and loss of the ability to stick to adjacent cells through epithelial-mesenchymal transition. Although there are several strongly recommended biomarkers for determining prognosis of metastatic castration-resistant prostate cancer, only few of them may help decide the selection of the optimal treatment option. The mode of treatment sequencing in metastatic castration-resistant prostate cancer will be based on the individual characteristics of the patient. In this study, we aimed to explain the correlation between the expression characteristics of periostin, integrin-alpha 4, and fibronectin in metastatic castration-resistant prostate cancer patients and their clinico-pathological data comprising Gleason score, PSA levels, and metastatic sites in the process of epithelial-mesenchymal transition. We evaluated by using Western blotting, periostin, integrin-alpha 4, and fibronectin expressions in peripheral blood samples of metastatic castration-resistant prostate cancer patients (n=40), benign prostatic hyperplasia patients (n=20), and the healthy control group (n=20). Associations between changes in the protein expressions and clinico-pathological parameters were also analyzed in the metastatic castration-resistant prostate cancer group. When comparing BPH and healthy groups with the metastatic castration-resistant prostate cancer group, a reduced expression of integrin-alpha 4 was found in metastatic patients, albeit being statistically insignificant (P>0.05). Protein expressions of periostin and fibronectin in the metastatic castration-resistant prostate cancer group were higher than those in the BPH and heathy groups (P<0.001). Increased periostin expression in metastatic patients was significantly associated with bone metastasis (P<0.05). Elevated periostin and fibronectin levels in metastatic castration-resistant prostate cancer patients may be appropriate targets of therapeutic intervention in the future. | |
dc.language.iso | en | |
dc.publisher | Sage Publications Inc | |
dc.relation.isversionof | 10.1177/1535370217728499 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Research & Experimental Medicine | |
dc.title | Do The Expressions of Epithelial-Mesenchymal Transition Proteins, Periostin, Integrin-Alpha 4 and Fibronectin Correlate With Clinico-Pathological Features and Prognosis of Metastatic Castration-Resistant Prostate Cancer? | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Experimental Biology And Medicine | |
dc.contributor.department | Üroloji | |
dc.identifier.volume | 242 | |
dc.identifier.issue | 18 | |
dc.identifier.startpage | 1795 | |
dc.identifier.endpage | 1801 | |
dc.description.index | WoS | |